港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化_老虎社区_美港股上老虎

港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化

智通财经2023-01-13

智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

虎头虎脑之鹰击长空
·2023-01-16
👍
回复
点赞
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2303826099?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-01-13 11:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2303826099","market":"sh","top_or_hot":-1,"title":"港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/861494.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-13 11:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/861494.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/861494.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/861494.html","article_id":"2303826099","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2303826099","pubTimestamp":1673581680,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，科济药业-B午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股","02171":"科济药业-B"},"translate_title":"Hong Kong stocks changed Keji Pharmaceutical-B (02171) rose by more than 12% before noon. The core pipeline product CT053 is expected to be commercialized this year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，2030年将增至289亿元，2022年至2030年的复合年增长率高达45.0%。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤（R/RMM）成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":626323471,"gmtCreate":1673850816793,"gmtModify":1673850818499,"author":{"id":"4098320575389210","authorId":"4098320575389210","name":"虎头虎脑之鹰击长空","avatar":"https://static.tigerbbs.com/0cc990f6c7bc363a015b013ff9572be1","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4098320575389210","authorIdStr":"4098320575389210"},"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/626323471","repostId":2303826099,"repostType":2,"repost":{"id":"2303826099","kind":"news","pubTimestamp":1673581680,"share":"https://www.laohu8.com/m/news/2303826099?lang=zh_CN&edition=full","pubTime":"2023-01-13 11:48","market":"sh","language":"zh","title":"港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2303826099","media":"智通财经","summary":"智通财经APP获悉，科济药业-B午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/02171\">科济药业-B</a>(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。</p><p>智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&amp;Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，2030年将增至289亿元，2022年至2030年的复合年增长率高达45.0%。</p><p>据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤（R/RMM）成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 科济药业-B(02171)午前涨超12% 核心管线产品CT053在今年有望商业化\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-01-13 11:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/861494.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/861494.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1585":"昨日强势股","02171":"科济药业-B"},"source_url":"http://www.zhitongcaijing.com/content/detail/861494.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2303826099","content_text":"智通财经APP获悉，科济药业-B(02171)午前涨超12%，截至发稿，涨12.29%，报19.74港元，成交额8656.07万港元。智通财经APP在《两款CAR-T领跑国内同行，估值仍处于底部的科济药业-B（02171）现补涨行情？》中指出，根据Frost&Sullivan预测，2021年国内CAR-T疗法的市场规模约为人民币2亿元，未来在癌症患者增加、政策优惠、患者负担能力提高的推动下，2030年将增至289亿元，2022年至2030年的复合年增长率高达45.0%。据悉，科济药业核心管线产品为CT053，被开发用于治疗失败的复发或难治性多发性骨髓瘤（R/RMM）成年患者，可特异性识别BCMA，令CAR-T细胞能够有效靶向及去除在细胞表面携带BCMA的多发性骨髓瘤细胞。2022年10月18日，CT053新药上市申请获国家药监局受理；此外，CT053在北美正开展Ib/II期临床试验，预计2023年递交BLA。分析表示，CT053在今年有望商业化。","news_type":1,"symbols_score_info":{"02171":1}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}